Functional polymorphism of the human arylamine N-acetyltransferase type 1 gene caused by C190T and G560 mutations

Pharmacogenetics

Volumn 8, Issue 1, 1998, Pages 67-72

  Butcher, Neville J ^a,b   Ilett, Kenneth F ^a   Minchin, Rodney F ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Human; N acetyltransferase; NAT1; Polymorphism

Indexed keywords

ACYLTRANSFERASE; CARCINOGEN; HETEROCYCLIC AMINE;

ACETYLATOR PHENOTYPE; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ACTIVITY; ENZYME ACTIVITY; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN EXPERIMENT; MONONUCLEAR CELL; NORMAL HUMAN; NUCLEIC ACID BASE SUBSTITUTION; OPEN READING FRAME; PHARMACOGENETICS; POPULATION; PRIORITY JOURNAL;

4-AMINOBENZOIC ACID; ACETYLATION; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENE FREQUENCY; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 0031884804     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199802000-00009     Document Type: Article

References (33)

1. Badawi AF, Hirvonen A, Bell DA, Lang NP, Kadlubar FF. Role of aromatic amine acetyltransferases, NAT1 and NAT2, in carcinogen-DNA adduct formation in the human urinary bladder. Cancer Res 1995; 55, 5230-5237.
2. Bell DA, Badawi AF, Lang NP, Ilett KF, Kadlubar FF, Hirvonen A. Polymorphism in the N-acetyltransferase 1 (NAT1) polyadenylation signal: association of NAT1*10 allele with higher N-acetylation activity in bladder and colon tissue. Cancer Res 1995a; 55, 5226-5229.
3. Bell DA, Stephens EA, Castranio T, Umbach DM, Watson M, Deakin M, Elder J, Hendrickse C, Duncan H, Strange RC. Polyadenylation polymorphism in the acetyltransferase 1 gene (NAT1) increases risk of colorectal cancer. Cancer Res 1995b; 55, 3537-3542.
4. Bozkurt A, Basci NE, Isimer A, Tuncer M, Erdal R, Kayaalp SO. Sulphamethoxazole acetylation in fast and slow acetylators. Int J Clin Pharm Ther Toxicol 1990; 28, 164-166.
5. Bradford MM. A rapid and sensitive method lor the quatilitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72, 248-254.
6. Chan K, Miners JO, Birkett DJ. Direct and simultaneous high-performance liquid chromatographic assay for the determination of p-aminobenzoic acid and its conjugates in human urine. J Chromatography 1988; 426, 103-109.
7. Cribb AE, Grant DM, Miller MA, Spielberg SP. Expression of monomorphic arylamine N-acetyltransferase (NAT1) in human leukocytes. J Pharmacol Exp Ther 1991; 259, 1241-1246.
8. 64 in the catalytic function of human N-acetyltransferase NAT1 and NAT2 by site-directed mutagenesis. Biochem J 1997; 323, 207-215.
9. Evans DAP. Pharmacogenetics. Am J Med 1963; 34, 639-662.
10. Evans DAP. N-Acetyltransferase. Pharmacol Ther 1989; 42, 157-234.
11. Evans DAP. Genetic factors in drug therapy: Clinical and molecular pharmacogenetics. Cambridge: University Press, 1993; 211-302.
12. Glowinski IB, Radtke HE, Weber WW. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol Pharmacol 1978; 14, 940-949.
13. Grant DM, Blum M, Beer M, Meyer UA. Monomorphic and polymorphic human arylamine N-acelyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 1991; 39, 184-191.
14. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochem Biophys Acta 1988; 948, 37-66.
15. Hein DW, Doll MA, Gray K, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acelyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res 1995; 53, 509-514.
16. Hein DW, Rustan TD, Ferguson RJ, Doll MA, Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol 1994; 68, 129-133.
17. Hein DW, Doll MA, Rustan TD, Ferguson RJ. Metabolic activation of N-hydroxyarylamines and N-hydroxarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res 1995; 55, 3531-3536.
18. Hughes NC, Janezic SA, McQueen KL, Jewett MAS. Castranio T, Bell DA, Grant DM. Identification and characterization of variant alleles of human acetyltranferase NAT1 with defective function using p-aminosalicylate as an in vivo and in vitro probe. Pharmacogenetics 1998; 8, 000-000.
19. Ilett KF, David BM, Detchon P, Castleden WM, Kwa R. Acetylation phenotype in colorectal carcinoma. Cancer Res 1987; 47, 1466-1469.
20. Kadlubar FF, Badawi AF. Genetic susceptibility and carcinogen-DNA adduct formation in human urinary bladder carcinogenesis. Toxicol Lett 1995; 82-83, 627-632.
21. Kato R. Metabolic activation of mulagenic heterocyclic aromatic amines from protein pyrolysates. CRC Crit Rev Toxicol 1986; 16, 307-348.
22. Kilbane AJ, Petroff T, Weber WW. Kinetics of acetyl CoA: arylamine N-acetyltransferase from rapid and slow acetylator human liver. Drug Metab Disp 1991; 19, 503-507.
23. Lang NP, Chu DZ, Hunter CF, Kendall DC, Flammang TJ, Kadlubar FF. Role of aromatic amine acetyltransferase in human colorectal cancer. Arch Surg 1986; 121, 1259-1261.
24. McQueen CA, Weber WW. Characterization of human lymphocyte N-acetyltransferase and its relationship to the isoniazid acetylator polymorphism. Biochem Genet 1980; 18, 889-904.
25. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF, Kadlubar FF. N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 1992; 185, 839-844.
26. Peters JH, Gordon GR, Brown P. The relationship between the capacities of human subjects to acetylate isoniazid, sulphanilamide and sulphamethazine. Life Sci 1965; 4, 99-107.
27. Probst-Hensch NM, Haile RW, Li DS, Sakamoto GT, Louie AD, Lin BK, Frankl HD, Lee ER, Lin HJ. Lack of association between the polyadenylation polymorphism in the NAT1 (acetyltransferase 1) gene and colorectal adenomas. Carcinogenesis 1996; 17, 2125-2129.
28. Vatsis KP, Weber WW. Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 gene locus. Arch Biochem Biophys 1993; 301, 71-76.
29. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV et al. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995; 5, 1-17.
30. Ward A, Hickman D, Gordon JW, Sim E. Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol 1992; 44, 1099-1104.
31. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev 1985; 37, 25-79.
32. Weber WW, Vatsis KP. Individual variability in p-aminobenzoic acid N-acetylation by human N-acelyltransferase (NAT1) of peripheral blood. Pharmacogenetics 1995; 3, 209-212.
33. Zenser TV, Lakshmi VM, Rustan TD, Doll MA, Deitz AC, Davis BB, Hein DW. Human N-acetylation of benzidine: role of NAT1 and NAT2. Cancer Res 1996; 56, 3941-3947.